Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Issue 9 (September 2013)

• Record Type: Journal Article
• Authors: Brioli, Annamaria; Kaiser, Martin F.; Pawlyn, Charlotte; Wu, Ping; Gregory, Walter M.; Owen, Roger; Ross, Fiona M.; Jackson, Graham H.; Cavo, Michele; Davies, Faith E.; Morgan, Gareth J.
• Is Part Of: Leukemia & lymphoma. Volume 54:Issue 9(2013:Sep.)
• Page Start: 1975
• Page End: 1981
• Publication Date: 2013-09
• Subjects: Myeloma -- cytogenetics -- chemotherapeutic approach -- thalidomide -- maintenance -- biological subtypes; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2012.760736
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Maintenance therapy is an attractive strategy for patients with multiple myeloma. However, the impact of maintenance thalidomide according to the underlying biology of the disease is still a matter of debate, with some studies suggesting that thalidomide is more beneficial in high risk disease, whilst others show the opposite. Biological risk groups defined by interphase fluorescence in situ hybridization (FISH) are powerful predictors of outcome. In this report we investigated the effect of maintenance thalidomide in different biological risk groups defined by different FISH categories. Our data show that maintenance thalidomide improves outcome in patients with biologically low risk disease, defined by the absence of adverse cytogenetic lesion or by the presence of hyperdiploidy alone. Conversely, thalidomide maintenance is detrimental for the overall survival of patients with biological high risk. We conclude that it is important to identify biologically low risk patients who will benefit from a maintenance strategy with thalidomide.